![[Search]](/static/images/search.gif){kind=small}
![[A-Z Index]](/static/images/az.gif){kind=small}
![[Contact]](/static/images/contact.gif){kind=small}
![[University of Cambridge]](/static/images/identifier2.gif){kind=small}
![[Talks.cam]](/static/images/talkslogosmall.gif)
Emily Bernstein, Icahn School of Medicine at Mount Sinai 
Thursday 21 February 2019, 13:00-14:00
Epigenetic control of malignant melanoma
- 👤 Speaker: Emily Bernstein, Icahn School of Medicine at Mount Sinai 🔗 Website
- 📅 Date & Time: Thursday 21 February 2019, 13:00 - 14:00
- 📍 Venue: CRUK CI Lecture Theatre
Abstract
Cutaneous melanoma is a highly aggressive skin cancer and one of the most challenging cancers in its therapeutic management. Emerging studies demonstrate that cancer is a result of a concerted action of genetic and epigenetic alterations. Our understanding of the ‘epigenetic landscape’ of melanoma remains poorly understood. We have shown a critical role for histone variants of the H2A family in regulating melanoma pathogenesis. For example, macroH2A acts as a barrier to melanoma growth and metastasis (Kapoor et al., Nature 2010), and H2A .Z.2 promotes melanoma growth by positively regulating transcription of E2F target genes (Vardabasso et al., Molecular Cell 2015). Studies will be presented of our ongoing efforts to identify key epigenetic players in melanoma progression and drug resistance, and to decipher the melanoma epigenome by comparing normal melanocytes with malignant melanoma cells.
Series This talk is part of the Cancer Research UK Cambridge Institute (CRUK CI) Seminars in Cancer series.
Included in Lists
- All Talks (aka the CURE list)
- Biology
- Cancer Research UK Cambridge Institute (CRUK CI) Seminars in Cancer
- CCC talks for website
- cri
- CRUK CI Lecture Theatre
- CRUK CI Seminars
- Graduate-Seminars
- Liam
- Life Sciences
- Life Sciences
- ME Seminar
- my_list
- other talks
- PMRFPS's
- se393's list
- sfm36
Note: Ex-directory lists are not shown.